Entity

Time filter

Source Type


Xu Q.,Shandong Academy of Sciences | Xu Q.,Shandong Lvdu Ante Veterinary Drug Industry Co. | Li J.,Northeast Agricultural University | Shen Z.,Shandong Academy of Sciences | And 6 more authors.
Journal of Chromatographic Science | Year: 2014

An HPLC-MS method has been developed and validated for the quantitative determination of milbemycin oxime (MBO) in dog plasma. The developed method has been then applied in in vivo clinical studies to obtain pharmacokinetics of MBO in blood after its oral administration. Samples were extracted using solid-phase extraction (SPE). Sample proteins were precipitated with acetonitrile (ACN) and sodium chloride (NaCl) and then diluted with methanol and water. Calibration standards were prepared by using plasma matrix and following the same SPE procedure. Chromatographic separation was performed on a Waters C18 packed column (3.5 μm particles diameter; 3 × 100 mm) with a C18 guard column (3.5 μm particles diameter; 3 × 20 mm). The mobile phase was an 85:15 (v/v) mixed solution of ACN and 5 mM ammonium acetate. The calibration curve was linear over a concentration range of 2.0-500 ng/mL with a limit of quantitation of 2.0 ng/mL. The oral administration of a pellet of 2.5 mg MBO produced blood concentrations ranging from 6.10 ± 0.92 to 78.81 ±4.38 ng/mL within 6 h, with a terminal half-time of 11.66 ±0.93 h. This study determined the suitability of the herein proposed method to investigate the pharmacokinetics of MBO after oral administration. © The Author [2013]. Published by Oxford University Press. All rights reserved. Source


Lu Y.,Liaocheng Peoples Hospital | Zhou L.,Liaocheng Second Peoples Hospital | Liu L.,Liaocheng Peoples Hospital | Feng Y.,Binzhou Medical College Hospital | And 4 more authors.
Disease Markers | Year: 2014

Background and Aim. It remains challenging to determine the inflammatory activity in Crohn's disease (CD) for lack of specific laboratory markers. Recent studies suggest that serum omentin-1 is associated with inflammatory response. We aimed to assess the potential of serum omentin-1 as a marker of disease activity in CD patients. Methods. Serum omentin-1 concentrations were determined by enzyme-linked immunosorbent assay (ELISA) in patients with CD (n = 240), functional gastrointestinal disorders (FGDs, n = 120), and healthy controls (HC, n = 60) and evaluated for correlation with disease activity. Expression of omentin-1 in colonic tissues from patients with CD was also analyzed by real-time PCR and Western blotting. Serum omentin-1 levels as an activity index were evaluated using a receiver operating characteristic (ROC) curve. Results. Serum omentin-1 concentrations were significantly decreased in active CD patients compared with patients in remission, FGDs, and HC (all P < 0.001). Expression of omentin-1 was decreased at mRNA and protein levels in inflamed colonic tissues in active CD than that in noninflamed colonic tissues. Serum omentin-1 levels were negatively correlated with disease activity in CD, better than C-reactive protein (CRP). Conclusion. Our results indicate that serum and colonic omentin-1 expressions are decreased in active CD patients. The correlation of serum omentin-1 with disease activity in CD is superior to that of CRP. Serum omentin-1 is a potential marker for CD disease activity. © 2014 Yan Lu et al. Source


Liu X.J.,Shandong University | Liu X.J.,Binzhou Medical College Hospital | Wang B.,Shandong University | Wang B.,Binzhou Medical College | And 4 more authors.
Genetics and Molecular Research | Year: 2015

Invasion, metastasis, and recurrence are the most common causes of death in patients with hepatocellular carcinoma (HCC) and are therefore critical factors for both therapy and prognosis. Current methods for diagnosis of HCC rely mainly on serological markers such as alpha-fetoprotein and liver enzymes, together with physical assessment and imaging techniques. The availability of more accurate serum markers may facilitate screening and early diagnosis, which will improve prognosis. This retrospective cohort analysis included 50 consecutive patients with cirrhosis and single or multifocal HCC and 40 control subjects with no liver disease or risk factors for viral hepatitis. Expression of epidermal growth factor-like domain 7 (EGFL7), osteopontin (OPN), and prostaglandin E2 (PGE2) were www.funpecrp.com.br detected using an enzyme-linked immunosorbent assay. The mean serum levels of EGFL7, OPN, and PGE2 in the HCC group were 132.11 pg/mL, 11.77 ng/mL, and 179.37 pg/mL, respectively, which were all significantly higher than the levels in the control group (23.03 pg/mL, 2.31 ng/mL, and 47.36 pg/mL, respectively; P < 0.001). Serum levels of EGFL7, OPN, and PGE2 levels may thus be useful for screening and surveillance of HCC among high-risk populations, and have the potential to improve prognosis of these patients. © FUNPEC-RP. Source


Wang W.M.,Binzhou Medical College Hospital | Liu Z.,Binzhou Medical College Hospital | Chen G.,Binzhou Medical College Hospital
Genetics and Molecular Research | Year: 2016

As the most common cardiac disease, myocardial infarction is followed by hypertrophy of cardiac myocytes and reconstruction of ventricular structure. The up-regulation of a series of factors including metalloproteinases, inflammatory factors, and growth factors after primary infarction lead to the hypertrophy, apoptosis, necrosis, and fibroblast proliferation in cardiac muscle tissues. Recent studies have reported on the potency of small interfering RNA (siRNA) in treating cardiac diseases. We thus investigated the efficacy of inducible co-stimulatory molecule (ICOS)-specific siRNA silencing in myocardial hypertrophy in a cardiac infarction rat model. This cardiac infarction model was prepared by ligating the left anterior descending coronary artery. ICOS-siRNA treatment was administered in parallel with non-sense siRNA. After 18 days, the cross-sectional area of cardiac muscle tissues and the left ventricle weight index were measured, along with ICOS mRNA and protein expression levels, and pathological staining. Compared to those in the control groups, in myocardial infarcted rats, the application of ICOS-siRNA effectively decreased the left ventricle weight index, as well as the surface area of cardiac myocytes. Both mRNA and protein levels of ICOS were also significantly decreased. HE staining was consistent with these results. In conclusion, ICOS-targeted siRNA can effectively silence gene expression of ICOS, and provided satisfactory treatment efficacy for myocardial cell hypertrophy after infarction. © FUNPEC-RP. Source


Li J.-Z.,Binzhou Medical College Hospital | Jin Y.-J.,Binzhou Medical College Hospital | Liu X.,Binzhou Medical College Hospital | Zhang L.-Y.,Binzhou Medical College Hospital
Chinese Journal of Oncology | Year: 2011

Objective: To investigate the association between serum TSH concentration and thyroid cancer incidence. Methods: Three hundred and thirty patients with thyroid tumors who underwent surgical treatment were included in this study (99 cases of malignancy and 231 cases of benign tumors). The data of their serum TSH level, gender, age, tumor type, and number of tumors detected by ultrasonic inspection were retrospectively analyzed, and their association with thyroid cancer incidence was explored. Results: The proportion of thyroid cancer in the groups of younger than twenty years and older than seventy years were 63. 0% and 58. 3%, respectively, significantly higher than that in the group of age between 60 and 69 years (23. 3%, P <0. 05). The incidence of thyroid cancer of the 81 male patients was 43. 2%, significantly higher than that in the 249 female patients (25. 7%, P = 0. 003). The incidence of thyroid cancer in the 112 patients with single nodule was 42.0%, significantly higher than that in the 218 patients with multiple nodules (23. 9%, P <0. 001). In the groups with TSH level lower than 0. 28 mIU/L and higher than 4. 20 mIU/L, the incidence of thyroid cancer were 54. 6% and 50. 0%, respectively, significantly higher than that in the group with TSH level between 0. 28 and 1. 44 mIU/L (16. 1%, P < 0. 05). The proportion of patients with thyroid cancer was also increased with the increasing serum TSH level in the normal range (P <0. 001). High serum TSH level (OR = 1. 465, P = 0. 014), male (OR = 1.964, P = 0. 016) and a single thyroid nodule (OR = 2. 090, P = 0. 006) are independent risk factors of thyroid cancer. Conclusion: The high serum TSH level, male, single thyroid nodule are factors leading to a high incidence of thyroid cancer. Source

Discover hidden collaborations